In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antiviral Sentiment

Executive Summary

The alarm bell is ringing for companies developing adenoviral vectors for gene therapies, particularly those meant to treat liver disease. But every firm in the field is now on alert.

You may also be interested in...



Gene Therapy’s Roller Coaster Ride

With big pharma on board, disappointments like the threatened EU market removal of pioneering Glybera and the Celladon trial failure give the field of gene therapy a bumpy ride after some major highs.

RNAi Start-Ups Continue Seeking, Attracting Support: Private Investors Like Nucleonics' Focus

Nucleonics, like other companies competing in the new field of RNAi, started out with big ambitions. Even before its Series A financing ran out, the company decided to focus on clinical goals. Nucleonics has just received a $41 million financing meant to see two drug candidates, presently still in preclinical testing, get through Phase II. Investors like its focus. Meanwhile, Alnylam still has big plans, which it's now hoping to finance through the public markets.

Targa Therapies SA

Targa Therapies marries gene therapy and monoclonal antibodies in its proprietary Antibody Delivery System, which it believes will help circumvent many of the flaws in current gene therapies.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV001277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel